New immunohistochemistry for B-cell lymphoma and Hodgkin lymphoma. Arch Pathol Lab Med. 2014;138(12):1666-72.Zhang, X.M. & Aguilera, N. 2014, "New immunohistochemistry for B-cell lymphoma and Hodgkin lymphoma", Archives of Pathology & Laboratory Medicine, vol. 138, no. 12, pp. 1666-...
9.Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23:91-103. 1...
L. P. F. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329, 987–994, doi: 10.1056/NEJM199309303291402 (1993). 18. Sehn, L. H. & Gascoyne, R. D. Diffuse large B-cell lymphoma: optimizing ...
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults, accounting for 30–40% of all non-Hodgkin lymphomas (NHL) in Western countries1. The introduction of chemoimmuno- therapy in the treatment of DLBCL has dramatically improved the outcome of these patients ...
Cutaneous B-Cell Lymphoma Diffuse Large B-Cell Lymphoma (DLBCL) Non-Hodgkin Lymphoma (NHL) Diffuse Large B-Cell Lymphoma (Non-Hodgkin Lymphoma) Treatment Protocols News & Perspective Mantle Cell Lymphoma: Drug Combo Improves PFS COVID Vaccine–Induced T-Cell Responses Help Compensate for B...
Non-Hodgkin lymphoma (NHL) is not a single disease entity, but rather a group of diseases, most of which are B cell in origin, though rare types of NHL are of T or natural killer cell origin. Several immunotherapeutic agents are available for the treatment of B-cell NHL, including the ...
弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)是成人非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)中最为常见的一种类型。欧美国家,DLBCL发病率约占NHL的30%~40%,亚洲国家超过40%[1]。目前,R-CHOP方案被认为是DLBCL标准一线治疗方案。然而,接受一...
1993年的新英格兰杂志发表了CHOP方案对比强化方案治疗晚期侵袭性非霍奇金淋巴瘤(non Hodgkin lymphoma, NHL)的III期随机对照临床研究的结果,认为强化方案并未能提高疗效,但此后多项的非随机性临床研究提示,强化的化疗方案有可能提高PMBL患者的疗效。在一项前瞻性II期临床研究中,Zanzani等应用MACOP-B方案联合放疗治疗初...
弥漫性大B细胞淋巴瘤(Diffuse large B‐cell lymphoma, DLBCL)是世界范围内最常见的侵袭性非霍奇金淋巴瘤(non‐Hodgkin lymphoma, NHL),在中国、日本和韩国分别占所有病例的40.8%、36.0%和48.4%目前一线(1L)治疗DLBCL的标准治疗(standard‐of‐care, SoC)是抗CD20单克隆抗体利妥昔单抗(rituximab, R)联合CHOP方案...
弥漫性大B细胞淋巴瘤(Diffuse large B‐cell lymphoma, DLBCL)是世界范围内最常见的侵袭性非霍奇金淋巴瘤(non‐Hodgkinlymphoma, NHL),在中国、日本和韩国分别占所有病例的40.8%、36.0%和48.4%目前一线(1L)治疗DLBCL的标准治疗(standard‐of‐care, SoC)是抗CD20单克隆抗体利妥昔单抗(rituximab, R)联合CHOP方案(...